Effect of glutamine on change in early postoperative intestinal permeability and its relation to systemic inflammatory response

Table 1 General data of two groups

	Placebo group	Glutamine group
Age (yr)	48.3 ± 12.2	48.3 ± 10.8
Male/Female	7/3	6/4
Weight (kg)	54.2 ± 11.1	56.7 ± 12.1

Table 2 Detailed clinical data of patients in two groups

Group	Case (n)	Sex	Age (yr)	Diagnosis	Operation type
Gln group	1	Male	55	Cardiac orifice cancer	Total gastrectomy
	2	Male	30	Acute suppurative cholangitis	Cholecystectomy choledochostomy
	3	Female	40	Rectal cancer	Anterior resection of rectum
	4	Male	47	Sigmoid cancer	Sigmoidectomy
	5	Male	62	Cardiac orifice cancer	Proximal subtotal gastrectomy
	6	Female	28	Rectal cancer	Anterior resection of rectum
	7	Female	52	Cholecystolithiasis	Cholecystectomy
	8	Male	49	Gastric cancer	Subtotal gastrectomy
	9	Male	60	Gastric cancer	Subtotal gastrectomy
	10	Male	60	Cardiac orifice cancer	Proximal subtotal gastrectomy
Placebo group	1	Male	50	Pancreas pseudocyst	Cyst-jejunal Roux-en-y anastomosis
	2	Female	56	Ascending colon cancer	Right semi-colectomy
	3	Female	60	Rectal cancer	Anterior resection of rectum
	4	Female	54	Sigmoid cancer	Sigmoidectomy
	5	Male	48	Cardiac orifice cancer	Proximal subtotal gastrectomy
	6	Male	43	Ascending colon cancer	Right semi-colectomy
	7	Male	64	Gastric cancer	Proximal subtotal gastrectomy
	8	Female	29	Gastric cancer	Proximal subtotal gastrectomy
	9	Male	43	Sigmoid cancer	Sigmoidectomy
	10	Male	36	Acute biliary pancreatitis	Selective cholecystectomy

Table 3 Serum levels of Gln in two groups (μmol/L)

Group	Before drug administration	7 d after drug administration
Placebo group	432.17 ± 142.68	250.78 ± 77.10b
Gln group	361.17 ± 161.25	583.22 ± 171.52ad

^aP < 0.05,

^bP < 0.01, vs before drug administration;

^dP < 0.01, vs pla-cebo group.

Table 4 Serum DAO levels in two groups (U/mL)

Group	Before drug	7 d after drug
	administration	administration
Placebo group	2.06 ± 0.48	3.18 ± 1.13
Gln group	2.26 ± 0.63	1.25 ± 0.65bd

^bP < 0.01 vs before administration;

^dP < 0.01 vs placebo group.

Table 5 Serum MDA levels in two groups (nmol/mL)

Groups	Before drug	7 d after drug
	administration	administration
Placebo group	3.94 ± 0.56	4.85 ± 0.63b
Gln group	4.46 ± 0.67	3.53 ± 0.59bd

^bP < 0.01 vs before drug administration;

^dP < 0.01 vs placebo group.

Table 6 Levels of serum endotoxin in two groups (EU/mL)

Group	Before drug	7 d after drug
	administration	administration
Placebo group	0.21 ± 0.07	0.25 ± 0.08
Gln group	0.23 ± 0.05	0.18 ± 0.06ab

^aP < 0.05 vs before drug administration;

^bP < 0.01 vs placebo group.

Table 7 Changes of urine L/M ratio in two groups

Group	Before drug	7 d after drug
	administration	administration
Placebo group	134.00 ± 18.48	194.83 ± 45.31b
Gln group	146.10 ± 20.21	117.47 ± 25.68ad

^aP < 0.05,

^bP < 0.01, vs before drug administration;

^dP < 0.01 vs pla-cebo group.